StockData

Crescent Biopharma vs Whitehawk Therapeutics

CBIO and WHWK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CBIO and WHWK compare

Crescent Biopharma is the larger company, worth 2.8 times as much as Whitehawk Therapeutics ($484M against $176M).

Whitehawk Therapeutics scores higher on the StockData Score (8 against 7 for Crescent Biopharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCBIOWHWK
Size and price
Market cap$484M$176M
Share price$13.04$3.08
Change, 1 year0.15%43.9%
Change, 5 years−92.7%−86.3%
Beta (5Y)1.852.33
Employees4423
StockData Score
Total score78 (better)
Valuation score01 (better)
Growth score1 (better)0
Performance score01 (better)
Health score66
Dividend score00
Valuation
P/B3.0×1.0× (better)
FCF yield−15.2% (better)−39.5%
Growth
Revenue growth (TTM)–−100%
Revenue growth, 5Y average1.3% (better)−12.6%
Profitability
Return on equity−63.5%−45.0% (better)
Financial health
Debt / equity0.000.00
Current ratio9.6617.38 (better)
Altman Z-score11.23 (better)6.35
Piotroski F-score–4
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions79.7%75.8%
Held by insiders38.6%49.9%
Insider net buying, 12 months$29.1M (better)−$2.6M
Short interest, % of float18.3%8.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.